Abstract
These studies examined the effects of a 21-day treatment regime with either the tricyclic antidepressant, desmethylimipramine (DMI), or the selective 5-HT uptake inhibitor, fluoxetine, on 5-HT2 receptors in rat brain, as assessed by selective agonist-mediated c-fos gene expression. Chronic, but not acute, treatment with fluoxetine (10 mg/kg, i.p. for 21 days) resulted in supersensitization of the response to an acute challenge (4 mg/kg, i.p.) with the selective 5-HT2 agonist, 2,5-dimethoxy-4-iodoamphetamine (DOI), both in frontal cortex and in hippocampus. Chronic treatment with DMI (10 mg/kg, i.p. for 21 days) resulted in a significant desensitization of the response to DOI. These findings are discussed in relation to the possible modes of action of these two clinically useful agents.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Amphetamines / pharmacology
-
Animals
-
Antidepressive Agents, Tricyclic / pharmacology*
-
Cerebral Cortex / drug effects
-
Cerebral Cortex / metabolism
-
Desipramine / pharmacology*
-
Fluoxetine / pharmacology*
-
Gene Expression / drug effects*
-
Genes, fos / drug effects*
-
Hippocampus / drug effects
-
Hippocampus / metabolism
-
Ketanserin / pharmacology
-
Male
-
RNA / biosynthesis
-
RNA / metabolism
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Serotonin / drug effects
-
Receptors, Serotonin / metabolism*
-
Selective Serotonin Reuptake Inhibitors / pharmacology*
-
Serotonin Antagonists / pharmacology
-
Serotonin Receptor Agonists / pharmacology
Substances
-
Amphetamines
-
Antidepressive Agents, Tricyclic
-
Receptors, Serotonin
-
Serotonin Antagonists
-
Serotonin Receptor Agonists
-
Serotonin Uptake Inhibitors
-
Fluoxetine
-
RNA
-
Ketanserin
-
4-iodo-2,5-dimethoxyphenylisopropylamine
-
Desipramine